NCT03337451View on ClinicalTrials.gov

Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 27, 2018

Primary Completion Date

January 10, 2019

Study Completion Date

January 10, 2019

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

OPN-305

Patients will receive study drug every 4 weeks

Trial Locations (1)

77030

Research Site, Houston

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Montefiore Medical Center

OTHER

collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

collaborator

New York Presbyterian Hospital

OTHER

lead

Opsona Therapeutics Ltd.

INDUSTRY